Provided By GlobeNewswire
Last update: Jun 17, 2025
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.
Read more at globenewswire.comNASDAQ:BRTX (11/13/2025, 8:20:19 PM)
1.25
-0.13 (-9.42%)
Find more stocks in the Stock Screener


